S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:AUTL

Autolus Therapeutics (AUTL) Stock Price, News & Analysis

$6.38
+0.14 (+2.24%)
(As of 03/28/2024 ET)
Today's Range
$6.19
$6.44
50-Day Range
$5.39
$7.25
52-Week Range
$1.61
$7.45
Volume
695,027 shs
Average Volume
1.62 million shs
Market Capitalization
$1.48 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.96

Autolus Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
24.8% Upside
$7.96 Price Target
Short Interest
Healthy
1.36% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.39mentions of Autolus Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.73) to ($0.49) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.96 out of 5 stars

Medical Sector

639th out of 938 stocks

Biological Products, Except Diagnostic Industry

105th out of 148 stocks

AUTL stock logo

About Autolus Therapeutics Stock (NASDAQ:AUTL)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

AUTL Stock Price History

AUTL Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views
Q4 2023 Autolus Therapeutics PLC Earnings Call
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Autolus Therapeutics's Earnings Outlook
AUTL Jun 2024 10.000 call
AUTL Mar 2024 2.500 call
Autolus Therapeutics Ltd (AUTL)
Vaxcyte, Inc.
See More Headlines
Receive AUTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
3/29/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AUTL
Fax
N/A
Employees
399
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.96
High Stock Price Target
$10.00
Low Stock Price Target
$4.80
Potential Upside/Downside
+24.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-208,380,000.00
Pretax Margin
-12,273.38%

Debt

Sales & Book Value

Annual Sales
$1.70 million
Book Value
$0.64 per share

Miscellaneous

Free Float
172,577,000
Market Cap
$1.48 billion
Optionable
Optionable
Beta
1.90
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Christian Martin Itin Ph.D. (Age 60)
    CEO & Director
    Comp: $2.42M
  • Dr. Martin Pule M.D. (Age 52)
    MBBS, Founder, Senior VP & Chief Scientific Officer
  • Mr. Robert F. Dolski (Age 54)
    Chief Financial Officer
  • Mr. Christopher Vann (Age 59)
    Senior VP & COO
  • Mr. David Brochu (Age 68)
    Senior VP & Chief Technical Officer
  • Mr. Alexander Swan
    Chief Human Resources Officer
  • Mr. Brent Rice (Age 58)
    Senior VP, Chief Commercial Officer & Site Head of US
  • Dr. Robert Iannone M.D. (Age 57)
    Executive VP of Global Head Of R&D and Non-Executive Director
    Comp: $169.93k
  • Ms. Olivia Manser
    Director of Investor Relations
  • Mr. Alex Driggs
    Senior VP of Legal Affairs & General Counsel and Secretary

AUTL Stock Analysis - Frequently Asked Questions

Should I buy or sell Autolus Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AUTL shares.
View AUTL analyst ratings
or view top-rated stocks.

What is Autolus Therapeutics' stock price target for 2024?

5 Wall Street research analysts have issued 12-month target prices for Autolus Therapeutics' stock. Their AUTL share price targets range from $4.80 to $10.00. On average, they predict the company's stock price to reach $7.96 in the next year. This suggests a possible upside of 24.8% from the stock's current price.
View analysts price targets for AUTL
or view top-rated stocks among Wall Street analysts.

How have AUTL shares performed in 2024?

Autolus Therapeutics' stock was trading at $6.44 at the beginning of the year. Since then, AUTL stock has decreased by 0.9% and is now trading at $6.38.
View the best growth stocks for 2024 here
.

Are investors shorting Autolus Therapeutics?

Autolus Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 3,150,000 shares, an increase of 13.7% from the February 29th total of 2,770,000 shares. Based on an average daily volume of 1,680,000 shares, the short-interest ratio is currently 1.9 days.
View Autolus Therapeutics' Short Interest
.

When is Autolus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AUTL earnings forecast
.

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics plc (NASDAQ:AUTL) announced its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.04. The firm had revenue of $0.24 million for the quarter, compared to analysts' expectations of $0.25 million. During the same quarter in the previous year, the firm earned ($0.72) EPS.

What ETF holds Autolus Therapeutics' stock?

Range Cancer Therapeutics ETF holds 44,025 shares of AUTL stock, representing 1.33% of its portfolio.

What other stocks do shareholders of Autolus Therapeutics own?
When did Autolus Therapeutics IPO?

Autolus Therapeutics (AUTL) raised $125 million in an initial public offering on Friday, June 22nd 2018. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

Who are Autolus Therapeutics' major shareholders?

Autolus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include TFG Asset Management GP Ltd (4.60%), Armistice Capital LLC (2.21%), Price T Rowe Associates Inc. MD (1.73%), Price T Rowe Associates Inc. MD (1.73%), Perpetual Ltd (1.19%) and Perceptive Advisors LLC (1.05%).

How do I buy shares of Autolus Therapeutics?

Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AUTL) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners